KeyBanc lowered the firm’s price target on HCA Healthcare (HCA) to $510 from $550 and keeps an Overweight rating on the shares. The firm notes that Q1 results were weaker than expected, highlighted by a 1.6% EBITDA miss driven by transitory flu/weather issues. Positively, performance improved exiting Q1 and HCA has above-average capacity adds hitting in 2026. However, investor confidence in HCA’s core EBITDA growth target of 6%-8% is lower and skeptics argue utilization continues to moderate, adds KeyBanc.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $496 from $551 at Barclays
- HCA: Baxter Maintains Hold as Soft Underlying Trends Prompt Trimmed EBITDA Outlook and Price Target Cut to $436
- Analyst Reaffirms Buy on Resilient Fundamentals and 2026 Outlook Despite Temporary Headwinds, While Lowering Price Target to $500
- HCA Healthcare Balances Solid Q1 With Payer Headwinds
- HCA Healthcare price target lowered to $525 from $590 at Jefferies